Dr. Aguirre on Daraxonrasib for RAS-Targeted Pancreatic Cancer Treatment

Targeted therapy nearly doubled overall survival for advanced pancreatic cancer patients in clinical testing.

Revolution Medicines presented clinical data for daraxonrasib at the ASCO cancer conference in May, where spontaneous applause broke out among the audience, according to lifesciencefocus.com. The trial included 500 patients with advanced, metastatic pancreatic cancer who had previously received treatment for the disease.

How The Molecular Glue Works

Daraxonrasib functions as a molecular glue that targets mutated proteins inside tumor cells. As reported by Targeted Onc, the medication couples cyclophilin A—a protein that typically does not interact with RAS—with the RAS protein itself, thereby shutting down the driver of cancer cell growth in pancreatic tumors.

Phoenix doctor testing new pancreatic cancer drug shown to potentially double patient survival rates — ABC15 Arizona

Preclinical data suggested the agent would be active in the disease. A phase 1 clinical trial subsequently read out with impressive efficacy in pancreatic cancer, Targeted Onc reported.

Survival Rates in The RASolute 302 Trial

A large randomized controlled trial, known as RASolute 302 (NCT06625320), followed the phase 1 data, Targeted Onc reported. Findings demonstrated that individuals with previously treated pancreatic cancer who had undergone earlier chemotherapy experienced roughly twice the overall survival duration relative to those treated with second-line chemotherapy alone.

Daraxonrasib approved by FDA: Pancreatic cancer drug shown to improve survival — 9NEWS

In the overall population, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard-of-care chemotherapy, according to Targeted Onc. Median progression-free survival reached 7.2 months compared with 3.6 months for chemotherapy, and the objective response rate was 30% versus 11%.

“RAS inhibition nearly doubled overall survival compared to second-line chemotherapy alone,” Aguirre said.

Dr. Aguirre on Daraxonrasib for RAS-Targeted Pancreatic Cancer Treatment
Photo: www.lifesciencefocus.com

Regulatory Approvals in The US and Europe

On August 26, 2026, the FDA granted approval to daraxonrasib for adult patients diagnosed with metastatic pancreatic adenocarcinoma who have undergone at least one prior systemic regimen or who are ineligible to receive multiagent systemic treatment.

Frequently Asked Questions About Daraxonrasib

What is the brand name of daraxonrasib?

The drug is also known by the trade name Rasonque, according to Life Science Focus.

Trial finds experimental pill for pancreatic cancer doubles survival time — CBC News

Which patients are eligible for the treatment?

As noted by Targeted Onc, the regulatory agency authorized this medication for adults suffering from metastatic pancreatic adenocarcinoma who have already undergone a minimum of one systemic treatment or who cannot tolerate multiagent systemic approaches.

What were the exact overall survival figures in the trial?

Median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard-of-care chemotherapy, according to Targeted Onc.

Daraxonrasib in Metastatic Pancreatic Cancer (RASolute 302) — NEJM Group